Likeability and Abuse Liability of Commonly Prescribed Opioids

Journal of Medical Toxicology

Volumn 8, Issue 4, 2012, Pages 335-340

  Wightman, Rachel ^a   Perrone, Jeanmarie ^b   Portelli, Ian ^a   Nelson, Lewis ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Abuse liability; Hydrocodone; Likeability; Morphine; Oxycodone

Indexed keywords

HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; MORPHINE; OXYCODONE; PLACEBO;

ABUSE LIABILITY; ARTICLE; DRUG EFFECT; DRUG MISUSE; HUMAN; LEGAL ASPECT; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84870709908     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-012-0263-x     Document Type: Article

References (19)

1. Gilson AM, Kreis PG (2009) The burden of the nonmedical use of prescription opioid analgesics. Pain Med 10(Suppl 2): S89-S100.
2. Substance Abuse and Mental Health Services Administration (2012) TEDS-Treatment Episode Data Set. At http://wwwdasis. samhsa. gov/webt/information. htm. Accessed 11 Aug. 2012.
3. Centers for Disease Control and Prevention (CDC) (2010) Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 59(23): 705-709.
4. IMS Institute for Healthcare Informatics (2011) The use of medicines in the United States: review of 2010. pp 1-37.
5. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1): 1-12.
6. Zacny JP (2003) Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. Psychopharmacology 165(2): 146-156.
7. Zacny JP, Gutierrez S (2003) Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology 170(3): 242-254.
8. Zacny JP, Gutierrez S, Bolbolan SA (2005) Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users. Drug Alcohol Depend 78(3): 243-252.
9. Zacny JP, Lichtor SA (2008) Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology 196(1): 105-116.
10. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ (2008) Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33(5): 1179-1191.
11. Wilsey BL, Fishman S, Li C-S, Storment J, Albanese A (2009) Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial. Pharmacol Biochem Behav 94(1): 98-107.
12. Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL (2010) Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology 212(2): 193-203.
13. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr (2008) The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98(3): 191-202.
14. Zacny JP, Gutierrez S (2009) Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend 101(1-2): 107-114.
15. Cicero TJ, Ellis MS, Paradis A, Ortbal Z (2010) Determinants of fentanyl and other potent μ opioid agonist misuse in opioid-dependent individuals. Pharmacoepidemiol Drug Saf 19(10): 1057-1063.
16. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH (2011) Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 8(1): 29.
17. Anonymous (2010) New guidelines create an "Oxy-free" ED. ED Manag 22(12): 136-137.
18. Raffa RB, Pergolizzi JV (2010) Opioid formulations designed to resist/deter abuse. Drugs 70(13): 1657-1675.
19. Cicero TJ, Ellis MS, Surratt HL (2012) Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 367(2): 187-189.